<DOC>
	<DOCNO>NCT02951754</DOCNO>
	<brief_summary>Methylphenidate ( MPH ) first-line pharmacological treatment adult Attention-Deficit/Hyperactivity Disorder ( ADHD ) . Nevertheless , considerable interindividual variability regard dose require , tolerability response rate MPH . The aim study address clinical genetic predictor MPH treatment outcomes ADHD .</brief_summary>
	<brief_title>Methylphenidate Adults With Attention Deficit/Hyperactivity Disorder</brief_title>
	<detailed_description>Methylphenidate ( MPH ) prescribe psychostimulant child adult Attention-Deficit/Hyperactivity Disorder ( ADHD ) . Meta-analyses systematic review show MPH safe efficacious attenuate core symptom ADHD , promote overall clinical improvement . However , many patient still show appropriate clinical response MPH treatment considerable interindividual variability regard dose require , tolerability response rate MPH . Therefore , essential address clinical genetic predictor MPH treatment outcomes ADHD .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Methylphenidate</mesh_term>
	<criteria>White Brazilian European descent Fulfillment Diagnostic Statistical Manual Mental Disorders , Fourth Edition , ( DSMIV ) diagnostic criterion ADHD Eligibility immediaterelease MPH ( IRMPH ) treatment Contraindication IRMPH use Current stimulant treatment Evidence clinically significant neurological disease might affect cognition ( e.g. , delirium , dementia , epilepsy , head trauma , multiple sclerosis ) Current past history psychosis Estimated intelligence quotient score low 70</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>ADHD</keyword>
	<keyword>Adults</keyword>
	<keyword>treatment</keyword>
	<keyword>Methylphenidate</keyword>
</DOC>